Transgene and Institut Bergonié Start the Phase 2 Part of the METROmaJX Trial
Transgene (Paris:TNG), a company that designs and develops viral-based immunotherapies announces that the first patient with soft tissue sarcoma (STS) has been treated in the Phase 2…
Read More...
Read More...